Latest Headlines

Latest Headlines

Cancer docs try to rally public behind plan to fight drug prices

Cancer doctors at the famed Mayo Clinic have been up in arms about escalating prices of cancer drugs. Now they have recruited a bunch of colleagues and are trying to rile up the public in hopes of starting a patient-based grassroots movement.

ViewRay goes public via reverse merger, raises almost $77M since IPO cancellation

The maker of the first MRI-guided radiation cancer therapy system, ViewRay, has raised more cash since it cancelled a planned $52 million IPO in April than it expected to raise in that offering. It's raised a total of $76.7 million--$26.7 million of that in connection with a reverse merger that it just completed on July 23 and another $50 million in debt from royalty investor CRG in late June.

Toronto startup gets $5M Series A round to nab FDA nod for surgical tissue imaging system

Perimeter Medical Imaging isn't alone in its aspirations to offer surgeons a better tool to visualize surgical tissue perimeters--but it is one of the newer entrants to the race. The startup has raised a $5 million Series A financing that it expects will be sufficient to complete an ongoing clinical trial, as well as to secure regulatory clearance for its first tissue imaging product.

EU funds development of a photonic-laser point-of-care cancer Dx device

European researchers from several companies and academic centers are working toward creating a photonic laser-based device that would enable the diagnosis and monitoring of cancer patients in the physician's office. The four-year project is funded via Horizon 2020, the largest and latest EU R&D initiative that's investing a total of almost €80 billion ($86.9 billion) from 2014 to 2020 to stimulate technology transfer.

ViewRay gets $50M in debt to back MRI-guided radiation therapy after IPO withdrawal

ViewRay has nabbed up to $50 million in debt financing from healthcare investor CRG after canceling a proposed $52 million IPO in April. The cash will go to help commercialize its MRI-guided radiation therapy as well as to refinance existing debt.

First paper from golden retriever lifetime study declares cancer a major target

In 2012, the Morris Animal Foundation launched its Golden Retriever Lifetime Study, which is expected to last 15 years and is aimed at identifying important risk factors for cancer and other diseases. Now the foundation has released its first paper from the study, which was published in a special cancer-themed issue of the journal Philosophical Transactions B.

U.K. researchers say earlier diagnoses of bladder cancer needed, especially among women

Women generally fare better than men after picking up cancer, but research presented at the Cancer Outcomes Conference in Belfast, Northern Ireland, found that the reverse is true among sufferers of bladder cancer. The information has informed a U.K. public advertising campaign to raise awareness of the disease.

Molecular Dx: Invitae drops prices as NIH starts 1,000-patient, molecular abnormalities cancer study

Newly public genetic information company Invitae has dropped prices for its genetic tests, just as the NIH says it will launch a study of the efficacy of cancer drugs by genetic mutation. Both are a testament to the rapidly evolving role of genetic information in patient treatment.

Singapore clinical group sees gene sequencing key in liver cancer treatment study

A Singapore-led clinical group has published a study of a novel approach to investigating how genes affect options to treat liver cancer, highlighting the city-state's growing role in oncology research.

Philips, MIT partner in $25M deal to develop innovative med tech, lighting

Royal Philips and the Massachusetts Institute of Technology (MIT) have partnered in a 5-year research alliance with a $25 million budget to develop novel product solutions in healthcare and lighting.